E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Haemophilia A is a hereditary bleeding disorder due to a deficiency of functional plasma coagulation FVIII |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060612 |
E.1.2 | Term | Hemophilia A |
E.1.2 | System Organ Class | 100000011915 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the immunogenicity of Voncento in Previously Treated Patients (PTPs) with haemophilia A.
|
|
E.2.2 | Secondary objectives of the trial |
To investigate the long-term safety of Voncento in previously treated patients with haemophilia A. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects meeting all of the following inclusion criteria may be enrolled into the study:
1. Capable of providing written informed consent and willing and able to adhere to all protocol requirements and / or the subject’s parent(s) or legally acceptable representative(s) capable of providing written informed consent.
2. Male subjects of any age.
3. Diagnosis of haemophilia A with plasma FVIII levels <2% documented in medical records
4. No history of FVIII inhibitors; or the successful completion of ITI treatment and documented FVIII inhibitor level <0.6 BU for at least 3 years (following ITI).
5. Subjects who have previously been treated with plasma-derived and / or recombinant FVIII product(s) for at least 150 EDs for the treatment of acute bleeding episodes, routine prophylaxis, and / or perioperative bleeding. |
|
E.4 | Principal exclusion criteria |
Subjects meeting any of the following exclusion criteria must not be enrolled into the study:
1. Participated in another clinical study with a plasma-derived or recombinant FVIII product other than Voncento® / Biostate® / Aleviate® / TBSF High Purity FVIII Concentrate within 30 days before the first administration of Voncento or at any time during the study.
2. Known history of FVIII inhibitors or suspicion of having FVIII inhibitors (however subjects who have completed successful ITI treatment and have had documented FVIII inhibitor level <0.6 BU for at least 3 years following ITI may be included) .
3. Currently receiving a therapy not permitted during the study (as defined in Section 9.3.1.4), which cannot be discontinued prior to enrolment into the study.
4. Previous participation in the current study.
5. Mental condition rendering the subject (or the subject’s legally acceptable representative[s]) unable to understand the nature, scope, and possible consequences of the study.
6. Known or suspected hypersensitivity to Voncento, or to any excipients of Voncento.
7. Any issue that, in the opinion of the investigator, would render the subject unsuitable for participation in the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary study endpoint is the incidence of FVIII inhibitor development. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The presence of FVIII inhibitors will be assessed by a central laboratory at every scheduled site visit (Visit 1-4), and additionally as required to assess any case of suspected inhibitors. |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints of the study are based on the AEs and AESIs reported:
• Nature and incidence of reported AEs, including SAEs.
• (S)AEs related to Voncento treatment.
• AESIs: thromboembolic events, hypersensitivity reactions, and suspected transmission of infectious agents.
• Lack of effect (ie, a less than expected response to Voncento treatment when given for a bleeding event) as assessed by the investigator. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
AEs after signing the informed consent form with a start date on or after the first dose of Voncento will be collected.
AEs will be assessed at every scheduled site visit (Visit 2-4). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |